



I Raise the Rates! December Edition

In this edition of I Raise the Rates (IRtR), you will find a variety of new resources from several public health partners, educational opportunities, and a brief selection of popular media articles related to immunization.

2025 Adult Immunization Schedule

CDC

UNITED STATES
2025

Recommended Adult Immunization Schedule for ages 19 years or older

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine	1vCOV-mRNA 1vCOV-aP5	Comirnaty/Pfizer-BioNTech COVID-19 Vaccine Spikevax/Moderna COVID-19 Vaccine Novavax COVID-19 Vaccine
Haemophilus influenzae type b vaccine	Hib	ActHib, Hibertix, PedvaxiHB
Hepatitis A vaccine	HepA	Havrix, Vaqta
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twintrix
Hepatitis B vaccine	HepB	Engerix-B, Hepisav-B, PreHevrio, Recombivax HB
Human papillomavirus vaccine	HPV	Gardasil 9
Influenza vaccine (inactivated, egg-based)	IV3	Multiple
Influenza vaccine (inactivated, cell-culture)	aIV3	Fluad
Influenza vaccine (live, attenuated)	HD-IV3	Fluzone High-Dose
Influenza vaccine (recombinant)	ccIV3	Fluceivax
Influenza vaccine (live, attenuated)	RV3	Flublok
Influenza vaccine (live, attenuated)	LAIV3	FluMist
Measles, mumps, and rubella vaccine	MWR	M-M-R II, Priorix
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM MenACWY-TT	Menveo MenQuadfi
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero Trumenba
Meningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/ MenB-FHbp	Penbraja
Mpox vaccine	Mpox	Jynneos
Pneumococcal conjugate vaccine	PCV15 PCV21	Vaxneuvance Prevnar 20 Capviva
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23
Poliiovirus vaccine (inactivated)	IPV	Ipol
Respiratory syncytial virus vaccine	RSV	Abrysvo, Arexvy, mResvia
Tetanus and diphtheria vaccine	Td	Tenivac
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel, Boostrix
Varicella vaccine	VAR	Varivax
Zoster vaccine, recombinant	RZV	Shingrix

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

11/21/2024

How to use the adult immunization schedule

- Determine recommended vaccinations by age (Table 1)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Assistants (www.aapa.org), American Pharmacists Association (www.pharmacist.com), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department.
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Questions or comments


Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.

Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/hcp/imz-schedules/app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/acip-recs/hcp/vaccine-specific/
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html
- General Best Practice Guidelines for Immunization: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/surv-manual/gipi/index.html

Scan QR code for access to online schedule



CDC U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION

The 2025 Adult Immunization Schedule approved by the Advisory Committee on Immunization Practices (ACIP) and adopted by the Centers of Disease Control and Prevention (CDC) director on October 24, 2024 is now available.

Use of Additional Doses of 2024-2025 COVID-19 Vaccine for Adults Aged > 65 Years and Persons Aged >6 Months with Moderate or Severe Immunocompromised: Recommendations of the Advisory Committee on Immunization Practices- United States, 2024-published in MMWR- December 12, 2024



Summary

In October 2024, ACIP recommended that all persons aged ≥ 65 years and persons aged 6 months–64 years with moderate or severe immunocompromise receive a second 2024–2025 COVID-19 vaccine dose 6 months after their last dose. Further, ACIP recommended that persons aged ≥ 6 months with moderate or severe immunocompromise may receive additional doses based on shared clinical decision-making.

[Access the Full December 12, 2024, MMWR Article Here](#)

COVID Vaccine Liability Protection Extended Through 2029

Department of Health and Human Services



Office of the Secretary

12th Amendment to Declaration Under the Public Readiness and Emergency Preparedness

Act for Medical Countermeasures Against COVID-19

ACTION: Notice of amendment.

SUMMARY: The Secretary issues this amendment pursuant to section 319F-3 of the Public Health Service Act to extend the duration of the Declaration to December 31, 2029, and to republish the Declaration in full.

DATES: This amendment is effective as of January 1, 2025.

FOR FURTHER INFORMATION CONTACT: L. Paige Ezernack, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, 400 7th St SW, Washington, DC 20024; 202-260-0365, paige.ezernack@hhs.gov.

SUPPLEMENTARY INFORMATION: The Public Readiness and Emergency Preparedness (PREP) Act authorizes the Secretary of Health and Human Services (the Secretary) to issue a Declaration to provide liability immunity to certain individuals and entities (Covered Persons) against any claim of loss caused by, arising out of, relating to, or resulting from the manufacture, distribution, administration, or use of medical countermeasures (Covered Countermeasures), except for claims involving “willful misconduct” as defined in the PREP Act. Under the PREP Act, a Declaration may be amended as circumstances warrant.

The PREP Act was enacted on December 30, 2005, as Public Law 109-148, Division C, section 2. It amended the Public Health Service (PHS) Act, adding section 319F-3, which addresses liability immunity, and section 319F-4, which creates a compensation program. These sections are codified at 42 U.S.C. 247d-6d and 42 U.S.C. 247d-6e, respectively. Section 319F-3 of the PHS Act has been amended by the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), Public Law 113-5, enacted on March 13, 2013, and the Coronavirus Aid, Relief, and

On December 11, 2024, HHS Secretary Xavier Becerra, issued a statement extended liability protections for COVID-19 vaccines, treatments and diagnostic tests under the Public Readiness and Emergency Preparedness Act through December 31, 2029. This extension follows the expiration of the COVID-19 public health emergency in May 2023 acknowledging the continued risk of future outbreaks and need for ongoing preparedness.

The amendment, effective as of January 1, 2025, provides immunity from liability to healthcare providers, including licensed pharmacists, pharmacy interns and pharmacy technicians, when administering COVID-19 vaccines and tests, along with seasonal flu vaccines. It also preempts state laws that would otherwise restrict professionals from dispensing or administering the countermeasures.

[Click Here to Read the Full Declaration](#)

Preliminary Estimated Flu Disease Burden 2024- 2025 Flu Season

CDC

Preliminary 2024–2025 U.S. Flu In-Season Disease Burden Estimates

Since October 1, 2024, CDC estimates there have been between:

5.3 Million-
9.3 Million



**Flu
Illnesses**

2.4 Million-
4.2 Million



**Flu
Medical Visits**

63,000-
140,000



**Flu
Hospitalizations**

2,700-
13,000



**Flu
Deaths**

Based on data from October 1, 2024, through December 28th, 2024

Because influenza surveillance does not capture all cases of flu, CDC provides these estimated ranges to better reflect the full burden of flu in the United States. These estimates are calculated using a mathematical model based on CDC's weekly influenza surveillance data and are preliminary and are updated weekly throughout the season.

FluVIEW




During each flu season, CDC provides weekly estimates of the burden of influenza in the United States. This web page provides weekly, preliminary estimates of the cumulative in-season numbers of flu illnesses, medical visits, hospitalizations, and deaths in the United States. These estimates of the burden of flu in the population and the impact of flu vaccination are then used to inform policy and communications related to flu.

[Click Here to Read More](#)

Weekly US Influenza Surveillance Report: Key Updates for Week 52, ending December 28, 2024





What to Know: Seasonal influenza activity continues to increase and is elevated across most of the country.

[Click Here to Access the Full Report](#)

RSV Vaccines: Questions Patients May Have and How to Answer

American Medical Association



RSV is responsible for 100,000 - 150,000 hospitalizations among adults 60 year or older each year, according to the CDC. While there are multiple RSV vaccines available for eligible older adults, some patients may require further guidance before they choose to receive their dose. The American Medical Association provides a list of frequently asked questions that providers can use to help communicate with their patients and encourage RSV vaccine uptake.

[Click Here to Read More](#)

Order Your 4 Free At-home COVID-19 Tests



Every U.S. household is eligible to order 4 free at-home tests through covidtests.gov.

The tests available for order:

- Are rapid antigen at-home tests, not PCR
- Can be taken at home or other locations. Give results within 30 minutes (no lab drop-off required)
- Can be used for testing even if you do not have COVID-19 symptoms
- Can be used for testing whether you are up to date on your COVID-19 vaccines or not
- Are also referred to as self-tests or over the counter (OTC) tests

[Click Here to Read More](#)

Upcoming Webinar

Vaccines, Autism, and Neurodiversity

Live Webinar
January 22nd, 2025
12:00pm-1:30pm Eastern Time

Vaccines, Autism, and Neurodiversity

GUEST SPEAKERS



Peter Hotez, MD, PhD

Texas Children's Hospital: Endowed Chair of Tropical Pediatrics | Co-Director, Texas Children's Hospital Center for Vaccine Development

Baylar College of Medicine: Dean, National School of Tropical Medicine | Professor, Departments of Pediatrics, Molecular Virology & Microbiology | Health Policy Scholar



Danielle Hall, MSW

Autism Society of America

Wednesday

January 22, 2025

12:00PM-1:30PM

Vaccines Did Not Cause Rachel's Autism: My Journey as a Vaccine Scientist, Pediatrician, and Autism Dad

Dr. Peter Hotez will speak on his renowned 2018 book, in which he discusses autism and its biological basis, addresses concerns and misinformation expressed by the anti-vaccine movement, and shares his personal story of raising a daughter with autism.

Accessible Vaccinations

Danielle Hall joins us from the Autism Society of America to speak on topics that include understanding autism, practical strategies for providers, and the Vaccine Education Initiative - a national program that addresses systemic barriers, while promoting vaccine education, confidence, and access.

CLICK TO REGISTER

More Details to Follow

immunizenj.org

Click to Register for the Webinar

New Jersey Immunization Network | 101 Morgan Lane Suite 301 | Plainsboro, NJ 08536 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!